Research
Hormonal
Substituting protease inhibitors with other antiretroviral drugs (such as nevirapine) can mitigate metabolic abnormalities like dyslipidemia and glucose intolerance, though reversal of fat redistribution is uncertain.
If you develop metabolic issues on your current HIV meds, ask your doctor about switching to a non-PI regimen (like nevirapine). This may fix your cholesterol and blood sugar problems without necessarily reversing the body shape changes, and it can still keep the virus suppressed.
ModerateQualifiesMEDIUM confidence
Substitution of PIs with other antiretroviral drugs can mitigate dyslipidemia and glucose intolerance, but whether reversal of lipodystrophy occurs remains unknown.
Why this rating
Based on observational data and some case reports; reversal of fat loss is explicitly stated as unknown.
Source
Lipodystrophy in Human Immunodeficiency Virus-Infected Patients
Dali Chen et al. · The Journal of Clinical Endocrinology & Metabolism · 2002
DOI 10.1210/jc.2002-020794
narrative_reviewCited 228×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- HIV protease inhibitor (PI) therapy causes lipodystrophy in HIV-infected patients, characterized by peripheral fat loss and truncal fat accumulation, along with metabolic abnormalities including insulin resistance and dyslipidemia.Good
- Increased physical activity and dietary restriction can reduce fat accumulation and improve metabolic complications in HIV patients with lipodystrophy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →